Ten year study confirms effectiveness of two-week radiotherapy for prostate cancer

	Prostate Cancer
	The latest prostate cancer news from News Medical

	Ten year study confirms effectiveness of two-week radiotherapy for prostate cancer Prostate cancer is the most commonly diagnosed cancer in men worldwide, accounting for more than 1.4 million new cases each year.

	Shorter radiation treatment after surgery found safe for prostate cancer patients For men who undergo a radical prostatectomy for the treatment of prostate cancer, post-surgery radiation therapy can play a vital role in reducing the risk of recurrence.

			Diabetes drug shows potential in slowing prostate cancer progression A drug used to treat type 2 diabetes may also be effective in slowing the progression of prostate cancer.

			New genetic mutation linked to increased prostate cancer risk in Ashkenazi Jewish men Identifying and classifying gene mutations - which are the permanent changes in a person's DNA genetic code - are critical in better understanding, and with research, eventually treating or preventing, the diseases with which they are linked.

			Genomic study of non-Hispanic Black veterans with prostate cancer yields key insights for precision medicine In the largest clinical genomic profiling study of non-Hispanic Black men with metastatic prostate cancer to date, researchers from Moffitt Cancer Center, University of Pennsylvania, University of California Los Angeles and the Veterans Affairs (VA) National Precision Oncology Program found key differences in tumor biology between non-Hispanic Black and non-Hispanic white veterans, but similar survival outcomes when both groups had equal access...

	New trial offers hope for men with aggressive prostate cancer Many men with aggressive prostate cancer can experience a high rate of recurrence despite treatment.

	Blood-based biomarkers predict therapy failure in prostate cancer patients New research has identified specific blood-based biomarkers that can predict the failure of prostate cancer treatment in both hormone-sensitive and castration-resistant patients.

	New AI test identifies prostate cancer patients who benefit from abiraterone A new artificial intelligence (AI) test can identify which men with prostate cancer will benefit most from the life-extending drug abiraterone, in clinical trial results presented by scientists from UCL and the Institute of Cancer Research.

	RANBP2 identified as key regulator in the progression of multiple solid tumors The nuclear pore complex protein RANBP2 has emerged as a critical factor in the development and progression of various solid malignancies.

Why did you receive this email?
You are receiving this email because you subscribed to updates from AZoNetwork UK Ltd. on one of our websites and requested to be notified of additional information.

Unsubscribe or Update Notification Preferences

Contact | About | Privacy Policy

- - - - - -

Registered Address:
AZoNetwork UK Ltd.,

Manchester | Sydney | Boston

Copyright © 2000-2025